Systemic Muscarinic Receptor Blockade
Oral glycopyrrolate blocks M3 receptors throughout the body, not just at sweat glands.
- M3: Receptor subtype (Primary target)
- Oral: Route (Systemic exposure)
- ~1 hr: Onset (Placeholder value)
- ~3 hr: Half-life (Placeholder value)
How systemic blockade occurs
Placeholder: drug diffuses via blood to all cholinergic targets.
Generalized Sweat Reduction Effect
Blocking eccrine gland receptors lowers sweat output across the whole body.
- Dose-dep.: Efficacy (Placeholder value)
- Eccrine: Target glands (Whole body)
- Days: Response time (Placeholder value)
- Generalized: Coverage (Vs. focal therapy)
Why sweat drops body-wide
Placeholder: systemic drug reaches glands everywhere, unlike topical therapy.
Dry Mouth Side Effect
Salivary gland blockade is the most common anticholinergic side effect.
- High: Incidence (Placeholder value)
- Dose: Severity driver (Higher dose, worse)
- Titration: Management (Placeholder value)
- Yes: Reversibility (Resolves off drug)
Mechanism of xerostomia
Placeholder: blocked salivary receptors reduce saliva flow.
Urinary Retention Risk
Bladder detrusor muscarinic blockade can impair voiding at higher doses.
- Older/BPH: Risk group (Placeholder value)
- Variable: Onset (Placeholder value)
- Advised: Monitoring (Placeholder value)
- Dose-dep.: Severity (Placeholder value)
Mechanism of retention risk
Placeholder: detrusor blockade reduces bladder contraction.
Dose Titration Risk-Benefit Balance
Clinicians titrate dose to maximize sweat control while limiting side effects.
- Balance: Goal (Efficacy vs. tolerability)
- Titrate up: Approach (Placeholder value)
- Side effects: Limiting factor (Placeholder value)
- Individualized: Outcome (Placeholder value)
Titration strategy
Placeholder: start low, increase slowly, watch side effects.
Placeholder: optimal dose maximizes balance metric shown above.